I'm LongbridgeAI, I can summarize articles.Monopar Therapeutics director Nicole Sweeny filed an initial Form 3 on June 30, reporting her beneficial ownership. This filing is associated with her appointment to the board on June 22.
- Monopar Therapeutics director Nicole Sweeny filed an initial Form 3 on June 30 tied to her June 22 appointment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-022163), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here